Found 387 Neoplasms trials
A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
UPCC 10519 / I5B-MC-Y001: An Open-Label Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma
The purpose of this program is to allow patients who, in consultation with their treating physician, feel it is in their best interest to continue to receive olaratumab. Only patients with soft tissue sarcoma who are already being treated with olaratumab may enter this program.
Study to Evaluate Study Drug XmAb 20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)
The primary purposes of this research study are to determine the safety and tolerability of dose levels of the investigational drug, XmAb20717, and if XmAb20717 works in treating advanced solid tumors that have progressed after treatment with standard cancer therapies or solid tumors for which there are no appropriate therapies …
UPCC 02818: A Phase I/IB Study of Avelumab in Combination with Gemcitabine for Advanced Renal Cell Carcinoma with Sarcomatoid Differentiation
This study is being done because doctors are trying to develop better methods for treating kidney cancer that has spread to other organs in the body. This study will evaluate the initial safety and effectiveness of an investigational drug, avelumab, given in combination with a chemotherapy drug (gemcitabine) that is …
UPCC 10219: Phase II Study Of Stromal Changes Detected By DCE- and DW-MRI In Response To PEGPH20 Combined With Chemotherapy In Subjects With Locally-Advanced Pancreatic Cancer
The research study is being conducted to determine the effects of PEGPH20 plus chemotherapy treatment on the MRI characteristics of pancreatic cancer tumors. Subjects will receive Gemcitabine, Abraxane, and PEGPH20.
ImmuneSense Study- Safety and Efficacy of IGV-001 an Autologus Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R in Newly Diagnosed Patients With Glioblastoma Multiforme
The purpose of this study is to see how safe the study medicine, IGV-001 plus standard of care (SOC), is and to compare IGV-001 with placebo (only standard of care) to see if it works in slowing GBM tumor regrowth. Participants for this study will be recruited from the patient …
A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy
Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06873600 administered as a single agent and then in combination with endocrine therapy. The study contains two parts, a Part 1 single agent dose escalation and combination endocrine therapy dose finding component and a Part …
UPCC 38922: A Phase I Multicenter Open-label First-in Human Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors
Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints) Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints) Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints)
A Pilot Single dose Open-Label Study of OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer Comparing Camera Imaging Systems
This is a small scale investigational study to compare different fluorescent camera imaging systems against the current standard (Visionsense VS3 Iridium system) for patients with Ovarian cancer. The VS3 is and FDA approved device currently in phase 3 clinical trials at the University of Pennsylvania and other institutions in combination …
UPCC 05122: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1
The purpose of this study is to see if sacituzumab govitecan can improve lifespans of patients with advanced TNBC and their tumor does not grow or spread when compared to chemotherapy (paclitaxel, or nab-paclitaxel, or the combination of gemcitabine and carboplatin), a commonly used treatment for previously untreated advanced TNBC.
ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA
Purpose is to determine if cemiplimab (given as infusion in the vein) will prevent cutaneous squamous cell cancer from returning after surgery and radiation. Subjects at least 18 years of age who have had surgery and radiation therapy for cutaneous squamous cell cancer, and there is a risk that this …
Please choose between Voice or SMS based delivery of verification code
or